Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency

Expert Review of Clinical Immunology

Volumn 9, Issue 5, 2013, Pages 477-488

  Zanichelli, Andrea ^a   Mansi, Marta ^a   Periti, Giulia ^a   Cicardi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

bradykinin receptor antagonist; C1 inhibitor; hereditary angioedema; kallikrein inhibitor

Indexed keywords

BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; STANOZOLOL; TRANEXAMIC ACID;

ABDOMINAL PAIN; ALLELE; AMENORRHEA; ANAPHYLAXIS; ANDROGEN THERAPY; ANGIONEUROTIC EDEMA; CARDIOPULMONARY BYPASS; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DYSPEPSIA; ERYTHEMA; FATIGUE; FIBRINOLYSIS; GENE MUTATION; HEART INFARCTION; HOME CARE; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LIVER ADENOMA; LUNG EMBOLISM; MENSTRUAL IRREGULARITY; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; PRURITUS; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SELF CARE; SIDE EFFECT; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VERTIGO; VIRILIZATION; WEIGHT GAIN;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; DISEASE MANAGEMENT; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; PEPTIDES; TREATMENT OUTCOME;

EID: 84877297728     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.13.22     Document Type: Review

References (97)

1. Zuraw BL. Clinical practice. Hereditary angioedema. N. Engl. J. Med. 359(10),1036 (2008
2. Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol. Immunol. 45(13),3544 (2008
3. Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma. Clin. Immunol. 6(1), 15 (2010
4. Binkley KE. Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions. Allergy Asthma. Clin. Immunol. 6(1), 16 (2010
5. Bowen T, Cicardi M, Farkas H et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J. Allergy Clin. Immunol. 114(3), 629-637 (2004
6. Bowen T, Cicardi M, Bork K et al. Hereditary angiodema: a current state-ofthe- art review, VII: Canadian Hungarian International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann. Allergy Asthma Immunol. 100(1 Suppl. 2), S30-S40 (2008
7. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J. Allergy Clin. Immunol. 124(1), 129-134 (2009
8. Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. Allergy 33, 330-341 (1962
9. Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C' 1-esterase. Am. J. Med. 35, 37-44 (1963
10. Silverman GA, Bird PI, Carrell RW et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276(36), 3-33296 (2001
11. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol. Med. 15(2), 69-78 (2009
12. Davis AE 3rd. C1 inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 6, 595-628 (1988
13. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin. Immunol. 114(1), 3-9 (2005
14. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N. Engl. J. Med. 347(8), 621-622 (2002
15. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351(9117), 1693-1697 (1998
16. Schapira M, Silver LD, Scott CF et al. Prekallikrein activation and highmolecular- weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 308(18), 1050-1053 (1983
17. Agostoni A, Aygören-Pürsün E, Binkley KE et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114(Suppl. 3), S51-S131 (2004
18. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 66(2), 192-196 (2011
19. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch. Intern. Med. 161(20), 2429 (2001
20. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am. J. Med. 119(3), 267-274 (2006
21. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus. Apher. Sci. 29(3), 235-238 (2003
22. Longhurst HJ, Farkas H, Craig T et al. HAE international home therapy consensus document. Allergy Asthma. Clin. Immunol. 6(1), 22 (2010
23. Cicardi M, Zanichelli A. Angioedema due to C1 inhibitor deficiency in 2010. Intern. Emerg. Med. 5(6), 481-486 (2010
24. Bowen T, Cicardi M, Farkas H et al. International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema. Allergy Asthma. Clin. Immunol. 6(1), 24 (2010
25. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch. Intern. Med. 161(5), 714-718 (2001
26. Berinert® (C1 esterase inhibitor, human), summary of product characteristics. CSL Behring GmbH, Marburg, Germany
27. Farkas H, Csuka D, Zotter Z et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J. Allergy Clin. Immunol. 131(3), 909-911.e5 (2013
28. Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur. J. Obstet. Gynecol. Reprod. Biol. 152(1), 44-49 (2010
29. Chinniah N, Katelaris CH. Hereditary angioedema and pregnancy. Aust. N. Z. J. Obstet. Gynaecol. 49(1), 2-5 (2009
30. Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J. Allergy Clin. Immunol. 124(4), 801-808 (2009
31. Craig TJ, Bewtra AK, Bahna SL et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study. Allergy 66(12), 1604-1611 (2011
32. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 52(1), 100-107 (2012
33. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur. J. Dermatol. 19(2), 147-151 (2009
34. Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL. Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int. Arch. Allergy Immunol. 157(4), 417-424 (2012
35. Cinryze® (C1 esterase inhibitor [human]), summary of product characteristics. ViroPharma Inc., PA, USA
36. Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 363(6), 513-522 (2010
37. Landmesser LM, Tillotson G, Mariano D. Site of care of nanofiltered C1 esterase inhibitor [human] (Cinryze) in patients with hereditary angioedema (HAE). Ann Allergy Asthma Immunol. 105, A113 (2010
38. Ruconest® (conestat alfa), summary of product characteristics. Pharming Group NV, Leiden, The Netherlands
39. Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J. Allergy Clin. Immunol. 126(4), 821-827.e14 (2010
40. Gröner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 52(10), 2104-2112 (2012
41. German Medical Profession's Drugs Committee. Severe thrombus formation of Berinert HS. Deutsches Ärzteblatt 97, B-864 (2000
42. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32(10), 902-909 (2012
43. Firazyr® (icatibant), summary of product characteristics. Shire plc., St Helier, Jersey
44. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med. 363(6), 532-541 (2010
45. Lumry WR, Li HH, Levy RJ et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann. Allergy Asthma Immunol. 107(6), 529-537 (2011
46. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 61(12), 1490-1492 (2006
47. Malbrán A, Di Marco P, Romero F. Treatment of hereditary angioedema with icatibant. Report of 163 attacks. Presented at: 6th European C1 Inhibitor Deficiency Workshop. Budapest, Hungary, 22-24 May
48. Kalbitor® (ecallantide), package insert. Dyax Corp., MA, USA
49. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 doubleblind, Phase 3 studies. J. Allergy Clin. Immunol. 128(1), 153-159.e4 (2011
50. Craig T, Riedl M, Dykewicz MS et al. When is prophylaxis for hereditary angioedema necessary? Ann. Allergy Asthma Immunol. 102(5), 366-372 (2009
51. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N. Engl. J. Med. 286(15), 808-812 (1972
52. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 295(26), 1444-1448 (1976
53. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N. Engl. J. Med. 287(9), 452-454 (1972
54. Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann. Intern. Med. 86(3), 306-308 (1977
55. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N. Engl. J. Med. 334(25), 1630-1634 (1996
56. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann. Allergy Asthma Immunol. 100(2), 153-161 (2008
57. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J. Allergy Clin. Immunol. 87(4), 768-773 (1991
58. Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc. 29(3), 225-231 (2008
59. Blohmé G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med. Scand. 192(4), 293-298 (1972
60. Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma. Clin. Immunol. 6(1), 19 (2010
61. Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol. 139(3), 379-394 (2005
62. Farkas H, Varga L, Széplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics 120(3), e713-e722 (2007
63. Bowen T. Review of consensus approaches to the diagnosis, therapy, and management of hereditary angioedema circa 2009. Immunology Allergy Clin. NA (2010) (In Press
64. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 57(6), 1005-1032 (1999
65. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb. Haemost. 86(2), 714-715 (2001
66. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb. Haemost. 70(2), 238-240 (1993
67. Henry DA, Carless PA, Moxey AJ et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst. Rev. 4, CD001886 (2007
68. Uozaki Y, Watanabe G, Kotou K, Ueyama K, Doi Y, Misaki T. Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass. Jpn J. Thorac. Cardiovasc. Surg. 49(5), 273-278 (2001
69. Günaldi M, Helvaci A, Yildirim ND, Kiskaç M, Küçükkaya RD. Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. Cardiol. J. 16(5), 458-461 (2009
70. Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 116(1), 91-97 (2009
71. Farkas H, Jakab L, Temesszentandrási G et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J. Allergy Clin. Immunol. 120(4), 941-947 (2007
72. Farkas H, Csuka D, Zotter Z, Varga L, Fust G. Prophylactic therapy in children with hereditary angioedema. J. Allergy Clin. Immunol. 131(2), 579-582 (2013
73. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J. Allergy Clin. Immunol. 117(4), 904-908 (2006
74. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int. Arch. Allergy Immunol. 154(1), 81-88 (2011
75. Reshef A, Moldovan D, Obtulowicz K et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 68(1), 118-124 (2013
76. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 112(1), 58-64 (2011
77. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J. Am. Dent. Assoc. 134(8), 1094 (2003
78. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N. Engl. J. Med. 304(9), 497-503 (1981
79. Bonser RS, Dave JR, John L et al. Complement activation before, during and after cardiopulmonary bypass. Eur. J. Cardiothorac. Surg. 4(6), 291-296 (1990
80. Bonser RS, Dave J, Morgan J et al. Complement activation during bypass in acquired C1 esterase inhibitor deficiency. Ann. Thorac. Surg. 52(3), 541-543 (1991
81. Lumry WR, Busse P, Baker J et al. Pre-procedure administration of C1 esterase inhibitor (human) (Cinryze) for the prevention of hereditary angioedema (HAE) attacks after medical, dental, or surgical procedures. Presented at: Annual Meeting of the American Academy of Allergy, Asthma & Immunology. San Francisco, CA, USA, 18-22 March 2011 (Abstract 903
82. Farkas H, Zotter Z, Csuka D et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor - a long-term survey. Allergy 67(12), 1586-1593 (2012
83. Kaplan AP, Joseph K. The bradykininforming cascade and its role in hereditary angioedema. Ann. Allergy Asthma Immunol. 104(3), 193-204 (2010
84. Cicardi M, Bork K, Caballero T et al.; HAWK (Hereditary Angioedema International Working Group). Evidencebased recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67(2), 147-157 (2012
85. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J. Allergy Clin. Immunol. 117(4), 904-908 (2006
86. Kreuz W, Martinez-Saguer I, Aygören- Pürsün E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 49(9), 1995 (2009
87. Sexton D, Faucette R, Viswanathan M et al. Discovery and characterization of a fully human monoclonal antibody inhibitor of plasma kallikrein for the treatment of plasma kallikrein-mediated edema. Presented at: Annual Meeting of the American Academy of Allergy, Asthma & Immunology. San Antonio, TX, USA, 22-26 February 2013
88. Bantia S, Zhang J, Wilson R et al. BCX4161, a small molecule orally bioavailable plasma kallikrein inhibitor for the treatment of hereditary angioedema. Presented at: Annual Meeting of the American Academy of Allergy, Asthma & Immunology. San Antonio, TX, USA, 22-26 February 2013
89. No authors listed. Three new drugs for hereditary angioedema. Med. Lett. Drugs Ther. 23, 66-67 (2010
90. Buehler PW. Cinryze pharmacology/ toxicology review memorandum. US FDA, December 2007. www.fda.gov/downloads/BiologicsBlood- Vaccines/ BloodBloodProducts/Approved- Products/LicensedProductsBLAs/ FractionatedPlasmaProducts/ UCM229783.pdf
91. US FDA: potential signals of serious risks/ new safety information identified by the Adverse Event Reporting System between January-March 2010. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/ AdverseDrugEffects/ucm216272.htm
92. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency. CHMP assessment reporfor Firazyr. 11-7-2008. www.emea.europa.eu/humandocs/PDFs/ EPAR/firazyr/H-899-eu6.pdf
93. Pfizer Canada Cyklokapron product monograph: oral: Pfizer Canada Inc. Intravenous Pfizer Canada Inc. 2003. www.pfizer.ca/en/our-products/products/ monograph/195
94. ClinicalTrials.gov. www.clinicaltrials.gov
95. CSL Behring. www.cslbehring.com
96. ViroPharma. www.viropharma.com
97. BioCryst. www.biocryst.com